UnitedHealth CEO Scrambles Amid Stock Plunge and Regulatory Scrutiny
UnitedHealth Group shares cratered 30% year-to-date, closing at $352.51 on September 12, 2025, as federal probes into Medicare billing practices rattled investors. The stock's 38.96% annual decline starkly contrasts with the S&P 500's 17.67% gain, exposing systemic underperformance.
CEO Stephen Hemsley's abrupt return to leadership in May 2025 failed to stem the bleeding. His recent White House lobbying mission - downgraded from a TRUMP meeting to staff-level talks - underscores the company's desperate bid to influence healthcare policy amid mounting regulatory headwinds.